Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in Pediatric Fibrosing ILD
NCT04093024Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2019
- Primary completion
- May 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 21
01
Overview
A Phase 3 trial of nintedanib in fibrosing interstitial lung disease (F-ILD), sponsored by Boehringer Ingelheim. Started Dec 2019; status: completed.
02
Drugs
nintedanib
03
Conditions
fibrosing interstitial lung disease (F-ILD)
Beyond the preview
Go deeper on NCT04093024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093024.